Update on anti-angiogenic treatment for malignant gliomas (Q38186658)

30 August 2017

title

Update on anti-angiogenic treatment for malignant gliomas (English)

1 reference

30 August 2017

main subject

angiogenesis inhibitor

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

John F de Groot

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 April 2014

1 reference

30 August 2017

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510742%20AND%20SRC:MED&resulttype=core&format=json

Malignant gliomas in adults

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Angiogenesis as a therapeutic target in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Antiangiogenic strategies for treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Time course of imaging changes of GBM during extended bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0380-6

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

1 reference

12 December 2020

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

1 reference

12 December 2020

Tumor angiogenesis: a quantitative method for histologic grading

1 reference

12 December 2020